Skip to main content
Premium Trial:

Request an Annual Quote

Agilent and Integrated Diagnostics Partner on Protein Biomarker Assays

NEW YORK (GenomeWeb News) – Agilent Technologies said today that it has partnered with Integrated Diagnostics to develop multiplexed protein biomarker-based assays for detecting diseases in their early stages.

The firms plan to develop high-throughput automated workflows for sample preparation and liquid chromatography mass spectrometry analysis, with the goal of accelerating biomarker discoveries by enabling screening of several hundred biomarkers in a single assay.

Under the collaboration, Integrated Diagnostics bought two Agilent 1290 Infinity UHPLC systems, two 6490 iFunnel triple quadrupole mass spectrometry systems, and two 1260 liquid chromatographers with ultraviolet detectors that it will use in the project.

"Integrated Diagnostics will bring expertise in assay development, technology strategy, study design, clinical development, commercialization and systems informatics to leverage the Agilent technology solution," Paul Kearney, president and chief scientific officer of Integrated Diagnostics, said in a statement.

He added that the partnership with Agilent "will allow us to realize the advantages of using a single technology platform from discovery and verification through to commercialization."